FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OIVID APPROVAL									
OMB Number:	3235-0287								
Estimated average bur	den								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Guyer Shelly D</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol NGM BIOPHARMACEUTICALS INC NGM								(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 12/03/2019								Officer ( below)	give title		Other (s below)	pecify			
(Street) SAN FRANCISCO CA 94103					4. If Amendment, Date of Original Filed (Month/Day/Year) 12/05/2019								Line)	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																			
		Tal	ble I - Non-	Deriva	tive S	ecuritie	s A	cquir	ed, D	ispos	ed o	of, or B	enefi	cially	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date,		e, Tr Co	Transaction Dispose Code (Instr. 5)			rities Acquired (A) o ed Of (D) (Instr. 3, 4 a				ily	Form:	Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership		
							C	ode V	/ Am	nount	(A) (D)	or F	rice	Transaction (Instr. 3 and	on(s) nd 4)			nstr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Cod	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivativ Security (Instr. 3 and 4)		vative	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	is Silly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exerci	isable	Expirat Date	tion	Title		unt or ber of es					
Stock Option (Right to Buy)	\$17.24	12/03/2019		A		49,197		(1	1)	12/02/2	2029	Common Stock	49,1	.97 <sup>(2)</sup>	\$17.24	49,197	7	D	

## **Explanation of Responses:**

- 1. The shares subject to the stock option are early exercisable and vest over a three-year period, with 1/3rd of the shares vested on December 3, 2020, and the remainder vesting in eight (8) equal quarterly installments measured from December 3, 2020.
- 2. This Form 4/A is being filed to report the correct number of shares underlying the stock option granted to the reporting person. The number reported on the Form 4 filed December 5, 2019 was incorrect due to a calculation error.

## Remarks:

/s/ Valerie Pierce, Attorney-in-

**Fact** 

\*\* Signature of Reporting Person

12/20/2019 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.